Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MLYCD | O95822 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TGM2 | P21980 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3987360 | 0.85 | CHRM1 (0.43) | MEN1KMT2AALDH1A1SIGMAR1 | |
| SCHEMBL3182429 | 0.83 | OPRM1 (0.48) | OPRM1OPRD1 | |
| SCHEMBL3175166 | 0.82 | HTR3E (0.41) | MEN1KMT2ALMNAPOLB | |
| SCHEMBL3173074 | 0.82 | HTR3E (0.41) | MEN1KMT2ALMNAPOLB | |
| SCHEMBL13395003 | 0.81 | OPRM1 (0.55) | OPRM1OPRD1 | |
| SCHEMBL3173338 | 0.81 | OPRM1 (0.55) | OPRM1OPRD1 | |
| SCHEMBL13394993 | 0.81 | OPRM1 (0.55) | OPRM1OPRD1 | |
| SCHEMBL3173450 | 0.78 | TRPA1 (0.43) | MEN1KMT2AALDH1A1HPGDGAA | |
| SCHEMBL13395000 | 0.77 | OPRM1 (0.49) | OPRM1OPRD1 | |
| SCHEMBL13395048 | 0.77 | OPRM1 (0.49) | OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093709-A1 | TRICYCLIC DELTA OPIOID MODULATORS | COATS STEVEN J | 2010-04-15 | — | — | US | claimed |
| US-7439239-B2 | Tricyclic δ- opioid modulators | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-10-21 | — | — | US | claimed |
| EP-1833826-A2 | TRICYCLIC DELTA-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-19 | — | — | EP | claimed |
| WO-2006069276-A2 | TRICYCLIC ō-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-29 | — | — | WO | claimed |
| US-20060135763-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-22 | — | — | US | claimed |
| US-20100093709-A1 | TRICYCLIC DELTA OPIOID MODULATORS | COATS STEVEN J | 2010-04-15 | — | — | US | disclosed |
| US-20100093709-A1 | TRICYCLIC DELTA OPIOID MODULATORS | COATS STEVEN J | 2010-04-15 | — | — | US | disclosed |
| US-20100093709-A1 | TRICYCLIC DELTA OPIOID MODULATORS | COATS STEVEN J | 2010-04-15 | — | — | US | disclosed |
| US-7652005-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-01-26 | — | — | US | disclosed |
| US-7652005-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-01-26 | — | — | US | disclosed |
| EP-1833826-B1 | TRICYCLIC DELTA-OPIOID MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-27 | — | — | EP | disclosed |
| US-20090042871-A1 | Tricyclic Delta-Opioid Modulators | COATS STEVEN J | 2009-02-12 | — | — | US | disclosed |
| US-20090042871-A1 | Tricyclic Delta-Opioid Modulators | COATS STEVEN J | 2009-02-12 | — | — | US | disclosed |
| US-7439239-B2 | Tricyclic δ- opioid modulators | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-10-21 | — | — | US | disclosed |
| US-7439239-B2 | Tricyclic δ- opioid modulators | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-10-21 | — | — | US | disclosed |
| EP-1833826-A2 | TRICYCLIC DELTA-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006069276-A2 | TRICYCLIC ō-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135763-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093709-A1 | TRICYCLIC DELTA OPIOID MODULATORS | OPRD1, OPRK1, OPRL1 | MEN1 4872/4885KMT2A 2053/4885ROCK2 2180/4885 |
| US-20060135763-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | MEN1 4869/4885KMT2A 2064/4885ROCK2 2549/4885 |
| US-20090042871-A1 | Tricyclic Delta-Opioid Modulators | OPRD1, OPRK1, OPRL1 | MEN1 4869/4885KMT2A 2064/4885ROCK2 2549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.